MIRA INFORM REPORT
|
Report Date : |
13.08.2008 |
IDENTIFICATION
DETAILS
|
Name : |
HUANGSHAN TIANMU PHARMACEUTICAL CO LTD |
|
|
|
|
Registered Office : |
No.45 Huangshan Middle Road, Tunxi District, Huangshan, Anhui
Province, 245000 PR |
|
|
|
|
Country : |
China |
|
|
|
|
Date of Incorporation : |
28.10.1997 |
|
|
|
|
Com. Reg. No.: |
341000000009905 |
|
|
|
|
Legal Form : |
One-Person Limited Liability Company |
|
|
|
|
Line of Business : |
Producing and Selling
Western Medicine, Chinese Medicine, and Raw Materials. |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Name
HUANGSHAN TIANMU PHARMACEUTICAL CO., LTD.
NO.45 HUANGSHAN MIDDLE ROAD, TUNXI DISTRICT, HUANGSHAN,
ANHUI PROVINCE, 245000 PR CHINA
45
TEL: 0086-559-2512225 FAX: 0086-559-2513184
EXECUTIVE SUMMARY
INCORPORATION DATE :
OCT. 28, 1997
REGISTRATION NO. :
341000000009905
REGISTERED LEGAL FORM : ONE-PERSON LIMITED LIABILITY COMPANY
CHIEF EXECUTIVE :
MR. CHENG BENLI (CHAIRMAN)
STAFF STRENGTH :
400
REGISTERED CAPITAL : CNY 30,000,000
BUSINESS LINE : MANUFACTURING
TURNOVER :
N/A (AS OF DEC. 31, 2007)
EQUITIES :
N/A (AS OF DEC. 31, 2007)
PAYMENT :
AVERAGE
RECOMM. CREDIT RANGE :
MODERATE AMOUNT
MARKET CONDITION :
AVERAGE
FINANCIAL CONDITION : N/A
OPERATIONAL TREND : STEADY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE :
CNY 6.86351 = USD 1
Adopted abbreviations
ANS - amount not stated
NS - not stated
SC - subject company (the company inquired by you)
NA - not available
CNY - China Yuan Renminbi
SC was registered as a One-person Limited Liability Company
at local Administration for Industry & Commerce (AIC - The official body of
issuing and renewing business license) on Oct. 28, 1997.
Company Status: One-person Limited Liability Company Single
person LLC refers to a limited liability company set up by only one natural
person or legal person as the single shareholder of it. The
minimum registered capital of Single person LLC is CNY100,000. The
shareholder’s capital contributes, as set out by the articles of
associations should be a lump-sum payment in full. One
natural person can only invest in and set up one limited liability company,
which is not permitted to invest in and set up a new Single person LLC. As to
any one-person limited liability company, the sole-investor nature of the
natural person or legal person shall be indicated in the registration
documents of the company and shall be indicated in the business license
thereof as well. The
regulation of Single person LLC should be set up by the shareholder The
regulation of Single person LLC has no shareholder meeting.
SC’s registered business scope includes producing small capacity
injection, troche (including antineoplastic agent), granular formulation, hard
capsule, pill (honeyed pill, granule and condensed pill), sirup, oral liquid
and tincture (including external application) (validity period as of 13th
December 2010)
SC is mainly
engaged in producing and selling western medicine, Chinese medicine, and raw
materials.
Mr. Cheng Benli is
legal representative and chairman of SC at present.
SC is known to have approx. 400 employees at present.
SC is currently operating at the above stated address, and this address
houses its operating office and factory in the industrial zone of Huangshan.
Our checks reveal that SC rents the premise, but SC’s accountant refused to release
the gross area of the premise.
http://www.tmpharm.com The design is professional and the content
is well organized. At present it is both in Chinese and English versions.
E-Mail: tmpharm@tmpharm.com
No significant events or changes were found during our checks with the
local Administration for Industry and Commerce.
MAIN
SHAREHOLDERS:
Name %
of Shareholding
Hangzhou Tianmushan Pharmaceutical Enterprise Co., Ltd. 100
Hangzhou Tianmushan Pharmaceutical Enterprise Co., Ltd.
is a listed company in Shanghai Stock Exchange Market with the code of 600671.
INCORPORATION DATE: Mar. 11, 1989
REGISTRATION NO.: 3301001003011
CHIEF EXECUTIVE: Zhang Pengfei
REGISTERED CAPITAL: CNY 121,778,880
Add: No.78 Shaoxi South Road, Linan,
Zhejiang Province. 78
Tel: 0571-6372229
Fax: 0571-6372229
l
Legal representative and chairman:
Mr. Cheng Benli, with university education. He is currently responsible
for the overall management of SC.
Working Experience(s):
At present Working
in SC as chairman and legal representative.
l
Sales Manager:
Mr. Ren Yisheng
Fax: 0559-2538593
SC is mainly
engaged in producing and selling western medicine, Chinese medicine, and raw
materials.
SC’s products mainly include: Menthol Crystals, Peppermint Oil Gentamycin
Injection Vitamin C Tablets Norfloxacin Capsules Lui Wei Di Huang Oral Liquid
Lui Wei Di Huang Condensed Pills Xiang Dan Injection、Yu Xin Cao
Injection He Che Da Zao Capsules Tamoxifen Citrate Tablets, etc.
SC sources its materials 90% from domestic market and 10% from the
overseas market. SC sells 60% of its products to overseas market, mainly in Nigeria, Pakistan, Indonesia, Macau, Hong Kong, etc,
and 40% in domestic market.
The buying terms of SC include Check, L/C, T/T and Credit of 30-60 days.
The payment terms of SC include Check, T/T, L/C, and Credit of 30-60 days.
SC is
not known to have any subsidiary at present.
Overall payment appraisal:
( ) Excellent (
) Good (X) Average (
) Fair ( ) Poor
( ) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment
experience (through current enquiry with SC's suppliers), our delinquent
payment and our debt collection record concerning SC.
Trade payment experience: SC did not
provide any name of trade/service suppliers and we have no other sources to
conduct the enquiry at present.
Delinquent
payment record: None in our database.
Debt collection record: No overdue amount
owed by SC was placed to us for collection within the last 6 years.
SC declined to release
its banking details.
SC’s management declined to release any financial information.
SC’s financial reports were not found during our checks with local AIC.
SC is considered a normally advancing concern with steady customers and
good base to meet its trade engagements.
Credit in the range of moderate amount can be considered.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.42.67 |
|
UK Pound |
1 |
Rs.80.92 |
|
Euro |
1 |
Rs.63.71 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)